Kaia home-training app can help manage COPD symptoms, study says

A senior woman sitting on a yoga mat looks at a smartphone with information about heart rate.
The app, currently in German, is only available through select insurers and providers. The company plans to have it translated into English and other languages in the near future. (Getty Images/doble-d)

A pilot clinical study demonstrated how Kaia Health’s artificial intelligence-based smartphone app could reduce a patient’s symptoms of chronic obstructive pulmonary disease.

The at-home digital intervention addresses physical and psychological factors of COPD, providing videos of cardiovascular and muscle exercises that are adjusted to an individual’s disease profile. It also includes audio-based relaxation exercises to help manage anxiety and depression.

Patients with questions can also contact a coach through the app, and access information on breathing and coughing techniques as well as nutrition and medication tracking.

The MedTech Conference

The MedTech Conference: September 23-25, Boston, MA

With over 3,000 attendees from 35 countries, The MedTech Conference features world-class plenary speakers, cross-cutting educational programming and business development opportunities. This is a prime opportunity to network, conduct business and share insights with medtech leaders. Register before July 26th and save $200!

In the study, published in the International Journal of Chronic Obstructive Pulmonary Disease, users showed clinically significant benefits in health-related quality of life scores after 20 therapy days compared to baseline, as well as some improvements in emotion and fatigue scores. Kaia Health said this suggests that a multidisciplinary digital treatment can help patients better manage their COPD.

“Conventional rehabilitation as a treatment for COPD is expensive and resource-intense, particularly in developed countries with a rapidly aging population and huge health care costs—which makes it difficult to integrate in healthcare systems,” said Konstantin Mehl, founder and CEO of the Munich, Germany-based Kaia Health. “Therefore it is underutilized even though international guidelines recommend its widespread use.”

“This clinical study indicates that, by digitizing therapy, we can democratize access to effective COPD treatment globally, which can be administered in the comfort of a patient’s home,” Mehl added. “This will empower patients to take control and self-manage their COPD with evidenced-based, non-pharmacological, affordable alternatives.”

The app, only available through select insurers and providers, is currently presented in German. The company plans to have it translated into English and other languages in the near future.

Suggested Articles

Eisai showed correlations between amyloid biomarkers in the blood and cerebrospinal fluid, bringing it closer to a simple blood test for Alzheimer’s.

Boehringer Ingelheim is licensing an autotaxin inhibitor from Bridge Biotherapeutics for €45 million and promising more than €1 billion in biobucks.

The series A sets ex-Gilead R&D chief Norbert Bischofberger up to advance efforts to hit historically undruggable targets.